Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 26, 2021	Mar. 27, 2020
Net sales	$ 558.0	$ 665.8
Cost of sales	307.6	382.0
Gross profit	250.4	283.8
Selling, general and administrative expenses	136.0	231.1
Research and development expenses	66.2	77.4
Restructuring charges, net	0.4	(1.8)
Non-restructuring impairment charges	64.5	0.0
Losses on divestiture	0.8	0.2
Opioid-related litigation settlement gain (Note 11)	0.0	(16.8)
Operating loss	(17.5)	(6.3)
Interest expense	(59.6)	(74.5)
Interest income	1.9	3.5
Other income, net	8.1	1.7
Reorganization Items	(93.5)	0.0
Loss from continuing operations before income taxes	(160.6)	(75.6)
Income tax benefit	(16.4)	(18.9)
Loss from continuing operations	(144.2)	(56.7)
Income from discontinued operations, net of income taxes	0.3	6.5
Net loss	$ (143.9)	$ (50.2)
Basic loss per share (Note 5):
Loss from continuing operations	$ (1.70)	$ (0.67)
Income from discontinued operations	0	0.08
Net loss	$ (1.70)	$ (0.60)
Basic weighted-averaged shares outstanding (in shares)	84.6	84.2
Diluted loss per share (Note 5):
Loss from continuing operations	$ (1.70)	$ (0.67)
Income from discontinued operations	0	0.08
Net loss	$ (1.70)	$ (0.60)
Diluted weighted-average shares outstanding (in shares)	84.6	84.2
Retained Earnings (Deficit)
Net loss	$ (143.9)	$ (50.2)